Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
Abstract Background Migraine clinical profile may change with age, making it necessary to verify that migraine treatments are equally safe and effective in older patients. These analyses evaluated the effects of patient age on the pharmacokinetics (PK), efficacy, and safety of galcanezumab for preve...
Main Authors: | Virginia L. Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Martha Port, Tonya Quinlan, Angelo Camporeale |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10194-020-01148-9 |
Similar Items
-
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
by: Angelo Camporeale, et al.
Published: (2018-11-01) -
Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01) -
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01) -
Photophobia and migraine outcome during treatment with galcanezumab
by: Francesca Schiano di Cola, et al.
Published: (2023-01-01) -
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
by: Stephen D. Silberstein, et al.
Published: (2019-06-01)